ismagilov/iStock via Getty Images J.P. Morgan has initiated coverage of Septerna ( NASDAQ: SEPN ) with an overweight rating, citing the company’s platform for GPCR drug design.
“Notwithstanding manifold newly actionable GPCR targets, we see Septerna ( SEPN ) executing a highly attractive pipeline strategy, focused on validated targets.
